Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
A joint research project between BioMed X and Boehringer Ingelheim has identified a new set of potential epigenetic targets for the treatment of two chronic lung diseases, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Epigenetics refers to DNA chemical modifications that can turn genes on or…
Treatment with Esbriet (pirfenidone) before and after cancer removal surgery reduces the risks of acute flares following the procedure in people with idiopathic pulmonary fibrosis (IPF) and lung cancer, a study finds. The findings were reported in “Perioperative pirfenidone treatment for lung cancer patients with…
Idebenone, an antioxidant molecule used to treat Alzheimer’s disease and other brain-damaging conditions, prevented lung damage in a mouse model of pulmonary fibrosis (PF), a study has found. The therapy also improved lung function in mice that had already developed the disease. The study, “…
Algernon Pharmaceuticals has announced its plans to launch its first Phase 2 clinical trial evaluating one of two repurposed compounds — NP-120 for the treatment of idiopathic pulmonary fibrosis (IPF) or NP-178 for inflammatory bowel disease (IBD) — in the second quarter of 2020. This follows…
Patients with idiopathic pulmonary fibrosis (IPF) in Canada face challenges in equal access to quality healthcare services at the national level, with drastic differences between provinces, according to the findings of a new report from the Canadian Pulmonary Fibrosis Foundation (CPFF) and Hoffmann-La Roche. The report, titled…
Delays in diagnosis and difficulty getting timely access to appropriate specialist care and treatment were highlighted as major gaps in care in a recent survey of people with pulmonary fibrosis (PF) and their healthcare providers. The survey results were discussed in the journal ERJ Open Research in a study,…
UCLA Health has launched a $20-million fundraising initiative to support the creation of a new research and treatment center for advanced lung diseases, including idiopathic pulmonary fibrosis (IPF), at the David Geffen School of Medicine at UCLA. The Lung Health Research Accelerator Fund…
Roche has acquired Promedior, a biotechnology company, and its full portfolio of molecules to possibly treat fibrotic diseases. The portfolio includes PRM-151, a lead therapy candidate for  idiopathic pulmonary fibrosis (IPF) advancing in clinical testing. PRM-151 is a synthetic engineered version of pentraxin-2, a protein that is able to…
A model of the human lung constructed with the help of tissue samples from 10 idiopathic pulmonary fibrosis (IPF) patients details changes in gene activity that precede evident fibrosis, a study reports. This model is a sort of genetic roadmap to IPF progression that may help researchers find treatments for…
Get regular updates to your inbox.
